Table of Contents
List of Figures
List of Abbreviations
Introduction
Chapter 1: Actor Network Theory
1.1. Examining the Importance of Actors
1.2. Actors Form Actor Networks
1.3. Translation
1.4. The Examination of Black Boxes
Chapter 2: Methods
Chapter 3: Description
3.1. The Drug Approval Process of Health Canada
3.2. The Drug Approval Process of the FDA
3.3. What Happens Once a Pharmaceutical Is Approved?
3.4. Financial Matters and Reviewing Pharmaceutical Applications
3.5. Linking International Pharmaceutical Control Agencies
Chapter 4: The Pharmaceutical Networks
4.1. Approving Pemoline for Sale
4.2. Withdrawing Pemoline From the Market
4.3. Approving Tolcapone for Sale 55
4.4. Withdrawing Tolcapone Off the Canadian Market
Chapter 5: Analysis
5.1. Discussing the Networked Actors
5.2. The Role of Scientifi c Publications
5.3. The Role of User Fees
5.4. The Role of Physicians in Marketing Practices
5.5. Failure of the Black Box—Adverse Reaction Reports
5.6. Analyzing International Links
5.7. Analyzing Differences Between Canada and the United States
5.8. Implications for Current Regulatory Thinking
Chapter 6: Conclusion
6.1. The Limitations of Actor Network Theory (ANT)
6.2. Examining the Limitations of My Research
6.3. Relating to the Larger Network
References
Index
